Prescriber Opinions on Biosimilars in Immunology

This report covers the 7MM (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and India and provides primary research findings from specialists surveyed for this report, including dermatologists, gastroenterologists, and rheumatologists who treat the most prevalent autoimmune conditions (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, Crohn’s disease, and plaque psoriasis) on the use of biosimilars for the treatment of these conditions. The report complements the publisher's Biosimilars in Immunology report.

A high proportion of all surveyed physicians indicated that they prescribed biosimilars to their immunology patients in 2019 with biosimilars experiencing greater use in cost conscious healthcare systems in Europe. The primary reason that all patients do not receive a biosimilar was due to patients’ doubts over the biosimilar’s efficacy As such, the main factor that might encourage increased prescribing of biosimilars is the availability of real world data for the biosimilar in each country where they are being used.

Scope

• Topics covered include: Biosimilar Prescription Overview and Perception; Biosimilar Prescription Incentives or Disincentives; Price Regulation and Discounts; Biosimilar Reimbursement; Factors Influencing Choice of Prescribed Biosimilar Brands; Future Directions of Biosimilar Use

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the 7MM and Indian biosimilars market.
• Drive revenues by understanding the key trends likely to impact the 7MM and Indian biosimilars market.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.